Results 51 to 60 of about 52,949 (209)
, 2012 Introduction: Evaluation of health-related quality-of-life ( HRQoL) and symptom improvement were preplanned secondary objectives for the overall population and posthoc analyses for epidermal growth factor receptor (EGFR ) mutation- positive/negative ...
楊志新;陳育民;郭漢彬 +1 more
core +1 more source
Cells, 2020 The property of drug-resistance may attenuate clinical therapy in cancer cells, such as chemoresistance to gefitinib in colon cancer cells. In previous studies, overexpression of PD-L1 causes proliferation and metastasis in cancer cells; therefore, the ...
Tung-Yung Huang +20 more
doaj +1 more source
Advanced Science, EarlyView.TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen +10 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley +1 more source
, 2012 Background: Epidermal growth factor receptor antagonists, such as gefitinib, erlotinib, and cetuximab, have been used in treating carcinomas . The efficacies have been proposed to correlate with skin reactions, but the most important predictive indicator
王修含;楊志新;邱顯清;胡賦?;詹智傑;廖怡華;陳小菁;朱家瑜 +1 more
core +1 more source
(S)-Pyrrolo[1,2-a]pyrazine-3-carboxamide Analogs as Dual Akt/JNK Modulators With Antiproliferative Effects in MDA-MB-468 Cells. [PDF]
ChemMedChemAmong 30 synthesized pyrrolo[1,2‐a]pyrazine analogs, compounds B1 and B3 showed strong and selective cytotoxicity toward TNBC cells, inducing apoptosis through Akt suppression and JNK activation. Triple‐negative breast cancer (TNBC) remains a major clinical challenge due to the absence of effective targeted therapies.
Hosseininasab N +10 more
europepmc +2 more sources
British Journal of Clinical Pharmacology, EarlyView.Background Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR‐TKIs) have substantially improved outcomes in non‐small cell lung cancer (NSCLC); however, the development of treatment resistance remains a major clinical challenge. This study examines the association between concomitant prescriptions of H1‐antihistamines (H1AHs) and ...
Van Thuan Nguyen +10 more
wiley +1 more source
BMEMat, EarlyView.This review highlights critical “translational gaps” in understanding micro‐ and nanoplastics impacts on gastrointestinal diseases, bridging exposure, detecting, and mechanistic toxicology. Abstract Micro‐ and nanoplastics (MNPs) have become pervasive environmental contaminants with increasing evidence linking them to adverse health outcomes.
Zhenli Diao +3 more
wiley +1 more source
Multi‐omics–driven precision medicine
iMeta, EarlyView.Multi‐omics‐driven precision medicine (MODPM) provides a multiscale, continuously learnable framework that integrates genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome profiles, and clinical data. Powered by artificial intelligence and foundation models, MODPM enables cross‐modal representation learning, contextual modeling ...
Huibo Li +20 more
wiley +1 more source
Anticancer potential of berberine: Molecular pathways and current clinical trial perspectives
JSFA reports, EarlyView.Abstract Cancer is constantly rising mortality rates due to its late prognosis, poor management, and expensive treatment. Multi‐sectoral approaches for cancer management include hygienic practices, synthetic drug exploitation, radiation therapy, and diet modifications.
Muhammad Maaz +10 more
wiley +1 more source